Patients With Atypical Symptoms of Depression Respond Better to Lithium Augmentation Than Patients Without Atypical Symptoms
Open Access
- 17 July 2026
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 154 (5) , 376-383
Abstract
Introduction: Understanding the differences in treatment response between subtypes of major depressive disorder (MDD) may help to prevent lengthy trial‐and‐error processes by identifying effective treatment options. The aim of the study was to investigate the impact of atypical features of MDD (MDD‐A) on the response to lithium augmentation (LA). Methods: In a multicenter prospective cohort study, response to LA was compared between patients with atypical symptoms of MDD (MDD‐A, n = 24) versus patients without atypical symptoms (MDD‐nA; n = 94) using a Cox regression analysis. Results: A total of 62.5% of patients with MDD‐A and 36.2% of patients with MDD‐nA responded to LA. Analysis adjusted for age, sex, sufficient lithium serum concentration, and symptom severity at baseline showed a significantly higher probability of patients with atypical symptoms to respond to LA (HR 2.20, p = 0.02). Conclusion: This is the first study investigating lithium‐response in patients with MDD‐A. The MDD‐A subtype may help to predict response to LA. Trial Registration: EudraCT number: 2008‐004182‐26; ClinicalTrials.gov identifier: DRKS00026205Keywords
This publication has 57 references indexed in Scilit:
- Polygenic Contributions to Lithium Augmentation Outcomes in Unipolar DepressionJAMA Psychiatry, 2025
- Depression with immuno-metabolic dysregulation: Testing pragmatic criteria to stratify patientsBrain, Behavior, and Immunity, 2024
- Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulationsEuropean Neuropsychopharmacology, 2023
- Individual Differences in Response to AntidepressantsJAMA Psychiatry, 2021
- Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the NESDA studyBrain, Behavior, and Immunity, 2020
- Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depressionEuropean Neuropsychopharmacology, 2017
- Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorderInternational Journal of Methods in Psychiatric Research, 2017
- The Promise and Limitations of Anti-Inflammatory Agents for the Treatment of Major Depressive Disorder2016
- Testing atypical depression definitionsInternational Journal of Methods in Psychiatric Research, 2005
- Treatment of Atypical Depression With Cognitive Therapy or PhenelzineArchives of General Psychiatry, 1999